Antibiotics, such as Amoxicillin, are extremely effectual when used appropriately prior to surgical procedures. The expiration of the potent antimicrobial drug Moxatag, also known as Amoxicillin, on October 13, 2020, paves the way for additional development of this generic powerhouse. Study results recently released in Infection Control and Hospital Epidemiology reveal that timing is crucial for the proper use of prophylactic antibiotic treatment. Patients who receive antibiotic prophylaxis approximately two hours before a surgical procedure have a significantly reduced risk of surgical site infections. This data, released by the Rambam Medical Center in Israel on January 15, 2014 indicates that post-surgical patients can absolutely benefit from antibiotic prophylaxis if timed perfectly. Patients who receive antibiotic doses either before the optimal two hour timeframe, or once incisions are made have proven to have notably diminished benefits for infection control.
The aforementioned ten year study in Israel involved 2,537 patients who were in need of preoperative antibiotic prophylaxis, specifically prior to cardiac surgery. Patients involved were given antibiotics at different times, including three hours before surgery, two hours prior to their procedure, one hour before surgery and after surgery was concluded. Data gleaned from this large and randomized study revealed that surgical site infections were least common among the patients who were given antibiotics approximately two hours prior to their surgery. Exactly 8.3 percent of the patient group that received preoperative antibiotic treatment exactly two hours before surgery developed a surgical site infection. This small number of patients is compared with 13.9 percent of patients who developed a surgical site infection, which included patients dosed with prophylactic antibiotics at different times, and not during two hour window prior to surgery. Antibiotics, specifically Amoxicillin are regularly dispensed to patients with heart conditions, such as a heart murmur, prior to both simple and complicated surgical procedures.
LGM Pharma is an Amoxicillin API supplier/distributor for research and development purposes, as well as the sole supplier/distributor of Amoxicillin TEVA API for compounding in the U.S.. Clients can be assured of quality API products and continuous support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk